Coya Therapeutics (COYA) Change in Accured Expenses (2022 - 2026)

Coya Therapeutics has reported Change in Accured Expenses for 5 years, with the latest figure at -$1.4 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 427.91% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$703869.0 (down 203.46% YoY) and the FY2025 annual result came in at $1.1 million, up 173.41% from the prior year.
• Change in Accured Expenses fell to -$1.4 million in Q1 2026 per COYA's latest filing, from $849207.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.7 million in Q4 2023 and troughed at -$1.4 million in Q1 2026.
• A 5-year average of -$4476.0 and a median of $166153.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses sank 875.4% in 2023, then soared 4110.61% in 2025.
• Over 5 years, Change in Accured Expenses stood at $102751.0 in 2022, then surged by 1567.72% to $1.7 million in 2023, then slumped by 101.24% to -$21174.0 in 2024, then jumped by 4110.61% to $849207.0 in 2025, then plunged by 262.76% to -$1.4 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.4 million, $849207.0, and -$1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.